Table 1. . Studies showing a link between 25(OH)D level and markers of melanoma prognosis.

Study (year)	Measure of prognosis	Sampling of 25(OH)D	Outcome	Ref.
Randerson-Moor et al. (2009)	Breslow thickness	At least 3–6 months after diagnosis	Inverse correlation between 25(OH)D level and Breslow thickness	[90]
Gambichler et al. (2013)	Breslow thickness	At baseline (up to 6 months after diagnosis) and 6 months later	Lower Breslow thickness was a predictor of high 25(OH)D concentration	[91]
Nurnberg et al. (2009)	CMM stage at diagnosis	Sampling between October and April (time between diagnosis and sampling highly variable)	Serum 25(OH)D levels significantly lower in stage IV vs stage 1 CMM	[92]
Newton-Bishop et al. 2009	Breslow thickness; relapse-free survival	Sampling 3–6 months after diagnosis	Significant trend toward lower 25(OH)D levels in association with higher Breslow thickness and lower relapse-free survival	[93]

25(OH)D: 25 hydroxyvitamin D; CMM: Cutaneous malignant melanoma.